ACOSS proposes alternative evidence-based and equitable savings to Australian health services

19 January 2015

The Australian Council of Social Service (ACOSS) has called on the federal government to heed the growing community concern about affordable, accessible universal health care; and to focus on evidence-based solutions to pull back wasteful spending in the health Budget.

"We know that our health system faces increasing costs with an ageing and growing population, but it's certainly not a crisis," said ACOSS CEO Cassandra Goldie, adding: "Savings measures should be selected that will either drive improved health outcomes, or cut real waste in existing spending."

She noted that Australia’s Prime Minister has asked for alternatives to the government's proposals for the Health Budget. “ACOSS welcomes the invitation. Our proposals are grounded in evidence and would improve the effectiveness of government spending in improving health outcomes for the greatest number of people,” Dr Goldie argued.

Urges the government to overhaul industry subsidies

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical